Hemostemix Inc

Research Hemostemix Inc (HEM) on Bullrun: market cap CAD 10.88M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerHEM
• ExchangeV
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCAD
• Market capCAD 10.88M
• Financial periodQ3 2025
• Net income-CAD 497.76K
• Free cash flow-CAD 2.91M

Valuation Snapshot

latest market cap is CAD 10.88M.

About Hemostemix Inc

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.

Frequently asked questions

What is Hemostemix Inc's market cap?

Hemostemix Inc's market capitalization is CAD 10.88M.

What does Hemostemix Inc do?

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada.